nach oben

Breast Cancer Research

Erschienen in:

01.08.2005 | Review

Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography

verfasst von: François Bénard, Éric Turcotte

Erschienen in: Breast Cancer Research | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

Although mammography remains a key imaging method for the early detection and screening of breast cancer, the overall accuracy of this test remains low. Several radiopharmaceuticals have been proposed as adjunct imaging methods to characterize breast masses by single-photon-emission computed tomography (SPECT) and positron-emission tomography (PET). Useful in characterizing indeterminate palpable masses and in the detection of axillary metastases, these techniques are insufficiently sensitive to detect subcentimetric tumor deposits. Their role in staging nodal involvement of the axillary areas therefore currently remains limited. Several enzymes and receptors have been targeted for imaging breast cancers with PET. [¹⁸F]Fluorodeoxyglucose is particularly useful in the detection and staging of recurrent breast cancer and in assessing the response to chemotherapy. Several other ligands targeting proliferative activity, protein synthesis, and hormone and cell-membrane receptors may complement this approach by providing unique information about biological characteristics of breast cancer across primary and metastatic tumor sites.

Nur mit Berechtigung zugänglich

Buist DS, Porter PL, Lehman C, Taplin SH, White E: Factors contributing to mammography failure in women aged 40–49 years. J Natl Cancer Inst. 2004, 96: 1432-1440.PubMedCrossRef

Viale G, Bosari S, Mazzarol G, Galimberti V, Luini A, Veronesi P, Paganelli G, Bedoni M, Orvieto E: Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer. 1999, 85: 2433-2438. 10.1002/(SICI)1097-0142(19990601)85:11<2433::AID-CNCR18>3.0.CO;2-3.PubMedCrossRef

Altinyollar H, Kapucuoglu N, Pak I, Berberoglu U: Lymphatic mapping and sentinel lymphadenectomy in early stage breast carcinoma. J Exp Clin Cancer Res. 2000, 19: 141-144.PubMed

Weaver DL, Krag DN, Ashikaga T, Harlow SP, O'Connell M: Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer. 2000, 88: 1099-1107. 10.1002/(SICI)1097-0142(20000301)88:5<1099::AID-CNCR22>3.0.CO;2-7.PubMedCrossRef

Hsieh PP, Ho WL, Yeh DC, Liu TJ, Wu CC, Lin JH, Wang SJ: Histopathologic analysis of sentinel lymph nodes in breast carcinoma. Chung Hua I Hsueh Tsa Chih (Taipei). 2000, 63: 744-750.

Canadian Cancer Statistics. [http://www.cancer.ca]

Fisher B, Osborne K, Margolese R, Bloomer W: Neoplasms of the breast. Cancer Medicine. Edited by: Holland J, Blast R, Morton D, Frei E, Kuge D, Weichselbaum R. 1997, Baltimore: Williams & Wilkins, 1: 2349-2429. 4

Jardines L, Callans LS, Torosian MH: Recurrent breast cancer: presentation, diagnosis, and treatment. Semin Oncol. 1993, 20: 538-547.PubMed

Peters W: Management of metastatic breast cancer. Adv Intern Med. 1995, 40: 341-364.PubMed

10.

Hustinx R, Benard F, Alavi A: Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002, 32: 35-46.PubMedCrossRef

11.

Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ: Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998, 4: 1334-1336. 10.1038/3337.PubMedCrossRef

12.

Kieswetter D, Kilbourn M, Landvatter S, Heiman D, Katzenellenbogen J, Welch M: Preparation of four fluorine-18-labeled estrogens and their selective uptake in target tissues of immature rats. J Nucl Med. 1984, 25: 1212-1221.

13.

Liberman M, Sampalis F, Mulder DS, Sampalis JS: Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature. Breast Cancer Res Treat. 2003, 80: 115-126. 10.1023/A:1024417331304.PubMedCrossRef

14.

Bender H, Friedrich E, Zamora PO, Guhlke S, Biersack HJ: Effects of induction of multi-drug resistance on accumulation of ^99mTc-sestamibi in vitro. Anticancer Res. 1997, 17: 1833-1839.PubMed

15.

Chiu ML, Kronauge JF, Piwnica-Worms D: Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med. 1990, 31: 1646-1653.PubMed

16.

Maublant JC, Zhang Z, Rapp M, Ollier M, Michelot J, Veyre A: In vitro uptake of technetium-99m-teboroxime in carcinoma cell lines and normal cells: comparison with technetium-99m-sestamibi and thallium-201. J Nucl Med. 1993, 34: 1949-1952.PubMed

17.

Piwnica-Worms D, Chiu ML, Croop JM, Kronauge JF: Enhancement of Tc-99m-sestamibi accumulation in multidrug resistant (MDR) cells by cytotoxic drugs and MDR reversing agents. J Nucl Med. 1993, 34: 140P-

18.

Palmedo H, Bender H, Grunwald F, Mallmann P, Zamora P, Krebs D, Biersack HJ: Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med. 1997, 24: 1138-1145.PubMed

19.

Yutani K, Shiba E, Kusuoka H, Tatsumi M, Uehara T, Taguchi T, Takai SI, Nishimura T: Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr. 2000, 24: 274-280. 10.1097/00004728-200003000-00017.PubMedCrossRef

20.

Danielsson R, Bone B, Perbeck L, Aspelin P: Evaluation of planar scintimammography with ^99mTc-MIBI in the detection of axillary lymph node metastases of breast carcinoma. Acta Radiol. 1999, 40: 491-495.PubMedCrossRef

21.

Taillefer R, Robidoux A, Turpin S, Lambert R, Cantin J, Leveille J: Metastatic axillary lymph node technetium-99m-MIBI imaging in primary breast cancer. J Nucl Med. 1998, 39: 459-464.PubMed

22.

Schillaci O, Scopinaro F, Danieli R, Tavolaro R, Picardi V, Cannas P, Colella AC: ^99mTc-sestamibi scintimammography in patients with suspicious breast lesions: comparison of SPET and planar images in the detection of primary tumours and axillary lymph node involvement. Nucl Med Commun. 1997, 18: 839-845.PubMedCrossRef

23.

Cwikla JB, Buscombe JR, Kolasinska AD, Holloway B, Hilson AJ: Evaluation of scintimammography as an additional test to conventional mammography in detection of breast cancer [in Polish]. Ginekol Pol. 2003, 74: 362-370.PubMed

24.

Fondrinier E, Muratet JP, Anglade E, Fauvet R, Berger V, Lorimier G, Jallet P: Clinical experience with ^99mTc-MIBI scintimammography in patients with breast microcalcifications. Breast. 2004, 13: 316-320. 10.1016/j.breast.2003.11.007.PubMedCrossRef

25.

Palmedo H, Biersack HJ, Lastoria S, Maublant J, Prats E, Stegner HE, Bourgeois P, Hustinx R, Hilson AJ, Bischof-Delaloye A: Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial. Eur J Nucl Med. 1998, 25: 375-385. 10.1007/s002590050235.PubMedCrossRef

26.

Tiling R, Linke R, Kessler M, Untch M, Sommer H, Brinkbaumer K, Becker I, Hahn K: Breast scintigraphy using 99mTc-sestamibi – use and limitations [in German]. Nuklearmedizin. 2002, 41: 148-156.PubMed

27.

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB: Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer. 1999, 85: 2410-2423. 10.1002/(SICI)1097-0142(19990601)85:11<2410::AID-CNCR16>3.0.CO;2-K.PubMedCrossRef

28.

Wilczek B, von Schoultz E, Bergh J, Eriksson E, Larsson SA, Jacobsson H: Early assessment of neoadjuvant chemotherapy by FEC-courses of locally advanced breast cancer using ^99mTc-MIBI. Acta Radiol. 2003, 44: 284-287. 10.1034/j.1600-0455.2003.00066.x.PubMedCrossRef

29.

Marshall C, Eremin J, El-Sheemy M, Eremin O, Griffiths PA: Monitoring the response of large (>3 cm) and locally advanced (T3-4, N0-2) breast cancer to neoadjuvant chemotherapy using ^99mTc-Sestamibi uptake. Nucl Med Commun. 2005, 26: 9-15. 10.1097/00006231-200501000-00003.PubMedCrossRef

30.

Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Lawton TJ, Barlow WE, Schubert EK, Mankoff DA: Residual tumor uptake of [^99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer. 2005, 103: 680-688. 10.1002/cncr.20831.PubMedCrossRef

31.

Kao CH, Tsai SC, Liu TJ, Ho YJ, Wang JJ, Ho ST, ChangLai SP: P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings. Cancer Res. 2001, 61: 1412-1414.PubMed

32.

Cwikla JB, Kolasinska A, Buscombe JR, Hilson AJ: Tc-99m MIBI in suspected recurrent breast cancer. Cancer Biother Radiopharm. 2000, 15: 367-372.PubMedCrossRef

33.

Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP: Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [¹⁸F]deoxyglucose. J Nucl Med. 1978, 19: 1154-1161.PubMed

34.

Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE: Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979, 6: 371-388. 10.1002/ana.410060502.PubMedCrossRef

35.

Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossman HB, Fisher S: ¹⁸F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer. 1991, 67: 1544-1550.PubMedCrossRef

36.

Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL: Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important?. J Nucl Med. 1995, 36: 1854-1861.PubMed

37.

Clavo AC, Brown RS, Wahl RL: Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995, 36: 1625-1632.PubMed

38.

Higashi K, Clavo AC, Wahl RL: Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993, 34: 414-419.PubMed

39.

Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F, Nathrath W, Schwaiger M: Glucose metabolism of breast cancer assessed by ¹⁸F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001, 42: 9-16.PubMed

40.

Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, Decise D, De Sanctis V, Greco M, Daidone MG, et al: Association between [¹⁸F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med. 1998, 25: 1429-1434. 10.1007/s002590050319.PubMedCrossRef

41.

Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL: Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology. 1993, 187: 743-750.PubMedCrossRef

42.

Crowe JP, Adler LP, Shenk RR, Sunshine J: Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol. 1994, 1: 132-140.PubMedCrossRef

43.

Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hortobagyi GN, Tilbury RS: Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer. 1993, 71: 3920-3925.PubMedCrossRef

44.

Scheidhauer K, Scharl A, Pietrzyk U, Wagner R, Gohring UJ, Schomacker K, Schicha H: Qualitative [¹⁸F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med. 1996, 23: 618-623. 10.1007/BF00834522.PubMedCrossRef

45.

Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y, Maddahi J, Brunicardi FC, Phelps ME, Glaspy JA: The application of positron emission tomographic imaging with fluoro-deoxyglucose to the evaluation of breast disease. Ann Surg. 1992, 216: 27-34.PubMedPubMedCentralCrossRef

46.

Wahl RL, Cody RL, Hutchins GD, Mudgett EE: Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1991, 179: 765-770.PubMedCrossRef

47.

Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M: Breast imaging with positron emission tomography and fluorine-18 fluoro-deoxyglucose: use and limitations. J Clin Oncol. 2000, 18: 3495-3502.PubMed

48.

Schirrmeister H, Kuhn T, Guhlmann A, Santjohanser C, Horster T, Nussle K, Koretz K, Glatting G, Rieber A, Kreienberg R, et al: Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med. 2001, 28: 351-358. 10.1007/s002590000448.PubMedCrossRef

49.

Brix G, Henze M, Knopp MV, Lucht R, Doll J, Junkermann H, Hawighorst H, Haberkorn U: Comparison of pharmacokinetic MRI and [¹⁸F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience. Eur Radiol. 2001, 11: 2058-2070. 10.1007/s003300100944.PubMedCrossRef

50.

Weinberg I, Majewski S, Weisenberger A, Markowitz A, Aloj L, Majewski L, Danforth D, Mulshine J, Cowan K, Zujewski J, et al: Preliminary results for positron emission mammography: real-time functional breast imaging in a conventional mammography gantry. Eur J Nucl Med. 1996, 23: 804-806. 10.1007/BF00843710.PubMedCrossRef

51.

Murthy K, Aznar M, Thompson CJ, Loutfi A, Lisbona R, Gagnon JH: Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med. 2000, 41: 1851-1858.PubMed

52.

Levine EA, Freimanis RI, Perrier ND, Morton K, Lesko NM, Bergman S, Geisinger KR, Williams RC, Sharpe C, Zavarzin V, et al: Positron emission mammography: initial clinical results. Ann Surg Oncol. 2003, 10: 86-91. 10.1245/ASO.2003.03.047.PubMedCrossRef

53.

Rosen EL, Turkington TG, Soo MS, Baker JA, Coleman RE: Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology. 2005, 234: 527-534.PubMedCrossRef

54.

Weinberg IN, Beylin D, Zavarzin V, Yarnall S, Stepanov PY, Anashkin E, Narayanan D, Dolinsky S, Lauckner K, Adler LP: Positron emission mammography: high-resolution biochemical breast imaging. Technol Cancer Res Treat. 2005, 4: 55-60.PubMedCrossRef

55.

Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR: Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology. 1997, 203: 323-327.PubMedCrossRef

56.

Avril N, Dose J, Janicke F, Bense S, Ziegler S, Laubenbacher C, Romer W, Pache H, Herz M, Allgayer B, et al: Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol. 1996, 14: 1848-1857.PubMed

57.

Utech CI, Young CS, Winter PF: Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med. 1996, 23: 1588-1593. 10.1007/BF01249621.PubMedCrossRef

58.

Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R, Micheli A, Asero S, Ferraris C, Gennaro M, et al: Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst. 2001, 93: 630-635. 10.1093/jnci/93.8.630.PubMedCrossRef

59.

Fehr MK, Hornung R, Varga Z, Burger D, Hess T, Haller U, Fink D, von Schulthess GK, Steinert HC: Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J. 2004, 10: 89-93. 10.1111/j.1075-122X.2004.21455.x.PubMedCrossRef

60.

Barranger E, Grahek D, Antoine M, Montravers F, Talbot JN, Uzan S: Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol. 2003, 10: 622-627. 10.1245/ASO.2003.12.019.PubMedCrossRef

61.

Wahl RL, Siegel BA, Coleman RE, Gatsonis CG, Group PETS: Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol. 2004, 22: 277-285. 10.1200/JCO.2004.04.148.PubMedCrossRef

62.

Lovrics PJ, Chen V, Coates G, Cornacchi SD, Goldsmith CH, Law C, Levine MN, Sanders K, Tandan VR: A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol. 2004, 11: 846-853. 10.1245/ASO.2004.11.033.PubMedCrossRef

63.

Bender H, Kirst J, Palmedo H, Schomburg A, Wagner U, Ruhlmann J, Biersack HJ: Value of ¹⁸fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res. 1997, 17: 1687-1692.PubMed

64.

Kim TS, Moon WK, Lee DS, Chung JK, Lee MC, Youn YK, Oh SK, Choe KJ, Noh DY: Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg. 2001, 25: 829-834. 10.1007/s002680020095.PubMedCrossRef

65.

Moon D, Hoh C, Silverman D, Glaspy J, Phelps M, Maddahi J: Accuracy of whole-body FDG PET for the detection of recurrent or metastatic breast carcinoma [abstract]. J Nucl Med. 1996, 37: 99P-

66.

Siggelkow W, Zimny M, Faridi A, Petzold K, Buell U, Rath W: The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res. 2003, 23: 1859-1867.PubMed

67.

Suarez M, Perez-Castejon MJ, Jimenez A, Domper M, Ruiz G, Montz R, Carreras JL: Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med. 2002, 46: 113-121.PubMed

68.

Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goerres GW: [¹⁸F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol. 2003, 129: 147-153.PubMed

69.

Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanley TJ, Gralow JR, Charlop A, Ellis GK, Lindsley KL, et al: ¹⁸Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol. 2001, 19: 3516-3523.PubMed

70.

Ahmad A, Barrington S, Maisey M, Rubens RD: Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer. 1999, 79: 478-482. 10.1038/sj.bjc.6690074.PubMedPubMedCentralCrossRef

71.

Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I: Detection of bone metastases in breast cancer by ¹⁸FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998, 16: 3375-3379.PubMed

72.

Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC: Comparing whole body ¹⁸F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol. 2002, 128: 325-328. 10.1007/s00432-002-0342-5.PubMedCrossRef

73.

Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R: Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993, 11: 2101-2111.PubMed

74.

Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J: Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?. J Clin Oncol. 1995, 13: 1470-1477.PubMed

75.

Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O, et al: Positron emission tomography using [¹⁸F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000, 18: 1676-1688.PubMed

76.

Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, Werner M, Dose J, Janicke F, Graeff H, et al: Positron emission tomography using [¹⁸F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000, 18: 1689-1695.PubMed

77.

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, Tseng J, Livingston RB: Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002, 43: 500-509.PubMed

78.

Stafford SE, Gralow JR, Schubert EK, Rinn KJ, Dunnwald LK, Livingston RB, Mankoff DA: Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol. 2002, 9: 913-921. 10.1016/S1076-6332(03)80461-0.PubMedCrossRef

79.

Van de Wiele C, De Vos F, Slegers G, Van Belle S, Dierckx RA: Radiolabeled estradiol derivatives to predict response to hormonal treatment in breast cancer: a review. Eur J Nucl Med. 2000, 27: 1421-1433. 10.1007/s002590000305.PubMedCrossRef

80.

Ribeiro-Barras MJ, Foulon C, Baulieu JL, Guilloteau D, Bougnoux P, Lansac J, Besnard JC: Estrogen receptor imaging with 17 alpha-[¹²³I]iodovinyl-11 beta-methoxyestradiol (MIVE2)–Part II. Preliminary results in patients with breast carcinoma. Int J Radiat Applic Instrum B Nucl Med Biol. 1992, 19: 263-267. 10.1016/0883-2897(92)90109-C.CrossRef

81.

Nachar O, Rousseau JA, Ouellet R, Rioux A, Lefebvre B, Ali H, van Lier JE: Scintimammography with 11beta-methoxy-(17alpha,20Z)-[¹²³I]iodovinylestradiol: a complementary role to ^99mTc-methoxyisobutyl isonitrile in the characterization of breast tumors. J Nucl Med. 2000, 41: 1324-1331.PubMed

82.

Bennink RJ, van Tienhoven G, Rijks LJ, Noorduyn AL, Janssen AG, Sloof GW: In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer. J Nucl Med. 2004, 45: 1-7.PubMed

83.

Kieswetter D, Katzenellenbogen J, Kilbourn M, Welch M: Fluorine-18 labeled estrogen: stereochemical and radiochemical considerations in the preparation of fluorine-18 labeled 16-fluoro estrogens by fluoride ion displacement reactions. J Org Chem. 1984, 49: 4900-4905. 10.1021/jo00199a031.CrossRef

84.

Tewson T: Synthesis of 16-alpha-fluoroestradiol (abstract). J Nucl Med. 1983, 24: P52-

85.

Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, Katzenellenbogen JA: Breast cancer: PET imaging of estrogen receptors. Radiology. 1988, 169: 45-48.PubMedCrossRef

86.

McGuire AH, Dehdashti F, Siegel BA, Lyss AP, Brodack JW, Mathias CJ, Mintun MA, Katzenellenbogen JA, Welch MJ: Positron tomographic assessment of 16 alpha-[¹⁸F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991, 32: 1526-1531.PubMed

87.

Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, Detert DD, Cutler PD, Katzenellenbogen JA, Welch MJ: Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995, 36: 1766-1774.PubMed

88.

Seimbille Y, Rousseau J, Bénard F, Ali H, van Lier JE: Synthesis of 2,16alpha- and 4,16alpha-[16alpha-¹⁸F]difluoroestradiols and their 11beta-methoxy derivatives for estrogen receptor imaging. J Labelled Cpd Radiopharm. 2001, 44: S348-S350.CrossRef

89.

Seimbille Y, Bénard F, van Lier JE: Synthesis of 16alpha-fluoro ICI 182,780 derivatives: powerful antiestrogens to image estrogen receptor densities in breast cancer by positron emission tomography. J Chem Soc Perkin Trans I. 2002, 20: 2275-2281. 10.1039/b205571f.CrossRef

90.

Seimbille Y, Rousseau J, Benard F, Morin C, Ali H, Avvakumov G, Hammond GL, van Lier JE: ¹⁸F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids. 2002, 67: 765-775. 10.1016/S0039-128X(02)00025-9.PubMedCrossRef

91.

Seimbille Y, Bénard F, Rousseau J, Pépin E, Aliaga A, Tessier G, van Lier JE: Impact on estrogen receptor binding and target tissue uptake of [¹⁸F]fluorine substitution at the 16alpha-position of fulvestrant (Faslodex; ICI 182,780). Nucl Med Biol. 2004, 31: 691-698. 10.1016/j.nucmedbio.2004.02.010.PubMedCrossRef

92.

Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ: Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001, 19: 2797-2803.PubMed

93.

Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL: Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002, 43: 1210-1217.PubMed

94.

Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, Peterson LM, Vallieres E, Wood DE: In vivo validation of 3'-deoxy-3'-[¹⁸F]fluorothymidine ([¹⁸F]FLT) as a proliferation imaging tracer in humans: correlation of [¹⁸F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002, 8: 3315-3323.PubMed

95.

Smyczek-Gargya B, Fersis N, Dittmann H, Vogel U, Reischl G, Machulla HJ, Wallwiener D, Bares R, Dohmen BM: PET with [¹⁸F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2004, 31: 720-724. 10.1007/s00259-004-1462-8.PubMedCrossRef

96.

Amano S, Inoue T, Tomiyishi K, Ando T, Endo K: In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Med. 1998, 39: 1424-1427.PubMed

97.

Huovinen R, Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M: Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. Br J Cancer. 1993, 67: 787-791.PubMedPubMedCentralCrossRef

98.

Yang D, Kuang LR, Cherif A, Tansey W, Li C, Lin WJ, Liu CW, Kim EE, Wallace S: Synthesis of [¹⁸F]fluoroalanine and [¹⁸F]fluorotamoxifen for imaging breast tumors. J Drug Target. 1993, 1: 259-267.PubMedCrossRef

99.

Kole AC, Nieweg OE, Pruim J, Paans AM, Plukker JT, Hoekstra HJ, Schraffordt Koops H, Vaalburg W: Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-¹¹C]tyrosine PET. J Nucl Med. 1997, 38: 692-696.PubMed

100.

Vilner BJ, John CS, Bowen WD: Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995, 55: 408-413.PubMed

101.

John CS, Vilner BJ, Schwartz AM, Bowen WD: Characterization of sigma receptor binding sites in human biopsied solid tumors [abstract]. J Nucl Med. 1996, 37: 267P-

102.

Simony-Lafontaine J, Esslimani M, Bribes E, Gourgou S, Lequeux N, Lavail R, Grenier J, Kramar A, Casellas P: Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors. Br J Cancer. 2000, 82: 1958-1966. 10.1054/bjoc.2000.1162.PubMedPubMedCentralCrossRef

103.

John CS, Bowen WD, Fisher SJ, Lim BB, Geyer BC, Vilner BJ, Wahl RL: Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1'-piperidinyl)ethyl]-3-[¹²⁵I]iodo-4-methoxybenzamide (P[¹²⁵I]MBA) for imaging breast cancer. Nucl Med Biol. 1999, 26: 377-382. 10.1016/S0969-8051(98)00104-8.PubMedCrossRef

104.

John CS, Vilner BJ, Bowen WD: Synthesis and characterization of [¹²⁵I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide, a new sigma receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells. J Medicinal Chem. 1994, 37: 1737-1739. 10.1021/jm00038a002.CrossRef

105.

John CS, Vilner BJ, Gulden ME, Efange SM, Langason RB, Moody TW, Bowen WD: Synthesis and pharmacological characterization of 4-[¹²⁵I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide: a high affinity sigma receptor ligand for potential imaging of breast cancer. Cancer Res. 1995, 55: 3022-3027.PubMed

106.

Caveliers V, Everaert H, John CS, Lahoutte T, Bossuyt A: Sigma receptor scintigraphy with N-[2-(1'-piperidinyl)ethyl]-3-¹²³I-iodo-4-methoxybenzamide of patients with suspected primary breast cancer: first clinical results. J Nucl Med. 2002, 43: 1647-1649.PubMed

107.

Collier TL, O'Brien JC, Waterhouse RN: Synthesis of [¹⁸F]-1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)-piperidine: a potential sigma-1 receptor radioligand for PET. J Labelled Cpd Radiopharm. 1996, 38: 785-793. 10.1002/(SICI)1099-1344(199609)38:9<785::AID-JLCR901>3.3.CO;2-2.CrossRef

108.

Waterhouse RN, Fawwaz R, Atuahene NF, Liu L, Schmidt AM, Collier TL: Biodistribution and micropet studies of the sigma-1 receptor radiotracer [¹⁸F]FPS in the MMTV transgenic mouse breast cancer model [abstract]. J Nucl Med. 2003, 44: 371P-

109.

Shiue C, Shiue GG, Benard F, Visonneau S, Santoli D, Alavi AA: N-(n-Benzylpiperidin-4-yl)-2-[¹⁸F]fluorobenzamide: a potential ligand for PET imaging of breast cancer. Nucl Med Biol. 2000, 27: 763-767. 10.1016/S0969-8051(00)00161-X.PubMedCrossRef

110.

Shiue CY, Shiue GG, Zhang SX, Wilder S, Greenberg JH, Benard F, Wortman JA, Alavi AA: N-(N-benzylpiperidin-4-yl)-2-[¹⁸F]fluorobenzamide: a potential ligand for PET imaging of sigma receptors. Nucl Med Biol. 1997, 24: 671-676. 10.1016/S0969-8051(97)00097-8.PubMedCrossRef

111.

Bruskin A, Sivaev I, Persson M, Lundqvist H, Carlsson J, Sjoberg S, Tolmachev V: Radiobromination of monoclonal antibody using potassium [⁷⁶Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI). Nucl Med Biol. 2004, 31: 205-211. 10.1016/j.nucmedbio.2003.08.005.PubMedCrossRef

112.

Zheng QH, Fei X, Liu X, Wang JQ, Bin Sun H, Mock BH, Lee Stone K, Martinez TD, Miller KD, Sledge GW, et al: Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [¹¹C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol. 2002, 29: 761-770. 10.1016/S0969-8051(02)00338-4.PubMedCrossRef

113.

Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003, 24: 389-427. 10.1210/er.2002-0007.PubMedCrossRef

Titel: Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography
verfasst von: François Bénard
Éric Turcotte
Publikationsdatum: 01.08.2005
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 4/2005
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1201

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2005

Connexin 43 mediated gap junctional communication enhances breast tumor cell diapedesis in culture

Overexpression of β1-chain-containing laminins in capillary basement membranes of human breast cancer and its metastases

Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence

TP53-binding protein variants and breast cancer risk: a case-control study

Benign breast disease, recent alcohol consumption, and risk of breast cancer: a nested case–control study

Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie